Mirtazapine vs. placebo in posttraumatic stress disorder: A pilot trial

被引:101
作者
Davidson, JRT
Weisler, RH
Butterfield, MI
Casat, CD
Connor, KM
Barnett, S
van Meter, S
机构
[1] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA
[2] Vet Adm Med Ctr, Durham, NC USA
[3] Carolinas Med Ctr, Charlotte, NC 28203 USA
[4] GlaxoSmithKline, Res Triangle Pk, NC USA
关键词
mirtazapine; efficacy; posttraumatic stress disorder;
D O I
10.1016/S0006-3223(02)01411-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Based on an earlier pilot study, as well as a theoretical consideration of its mechanism of action, we undertook a placebo-controlled, double-blind trial of mirtazapine in posttraumatic stress disorder. Methods: Twenty-nine patients were randomized to receive drug up to 45 mg/day or placebo double-blind on a 2:1 ratio for 8 weeks, with data being available for analysis in 26. Primary outcome measures comprised the Short Posttraumatic Stress Disorder Rating Interview (SPRINT) Global Improvement item and total score. Secondary measures comprised the Davidson Trauma Scale, Structured Interview for Posttraumatic Stress Disorder and Hospital Anxiety Depression Scale. Adverse events were also measured. Results: On the Short Posttraumatic Stress Disorder Rating Interview Global Improvement measure, rates Of response were 64.7% and 20.0% for mirtazapine and placebo. Treatment effects in favor of mirtazapine were noted on the Short Posttraumatic Stress Disorder Rating Interview global, Structured Interview for Posttraumatic Stress Disorder, and Hospital Anxiety Depression Scale anxiety subscale scores. The drug was well tolerated. Conclusions: Mirtazapine was more effective than placebo on some measures in posttraumatic stress disorder and general anxiety symptoms. (C) 2003 Society of Biological Psychiatry.
引用
收藏
页码:188 / 191
页数:4
相关论文
共 23 条
[1]   A review of central 5-HT receptors and their function [J].
Barnes, NM ;
Sharp, T .
NEUROPHARMACOLOGY, 1999, 38 (08) :1083-1152
[2]   Efficacy and safety of sertraline treatment of posttraumatic stress disorder - A randomized controlled trial [J].
Brady, K ;
Pearlstein, T ;
Asnis, GM ;
Baker, D ;
Rothbaum, B ;
Sikes, CR ;
Farfel, GM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (14) :1837-1844
[3]   Olanzapine in the treatment of post-traumatic stress disorder: a pilot study [J].
Butterfield, MI ;
Becker, ME ;
Connor, KM ;
Sutherland, S ;
Churchill, LE ;
Davidson, JRT .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2001, 16 (04) :197-203
[4]  
Cohen J., 1998, Statistical Power Analysis for the Behavioral Sciences, V2nd
[5]  
Connor K M, 2001, CNS Spectr, V6, P850
[6]   Fluoxetine in post-traumatic stress disorder - Randomised, double-blind study [J].
Connor, KM ;
Sutherland, SM ;
Tupler, LA ;
Malik, ML ;
Davidson, JRT .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 175 :17-22
[7]  
CONNOR KM, 1999, INT CLIN PSYCHOPHARM, V13, P111
[8]  
Davidson J R, 1997, Depress Anxiety, V5, P127, DOI 10.1002/(SICI)1520-6394(1997)5:3<127::AID-DA3>3.0.CO
[9]  
2-B
[10]   Assessment of a new self-rating scale for posttraumatic stress disorder [J].
Davidson, JRT ;
Book, SW ;
Colket, JT ;
Tupler, LA ;
Roth, S ;
David, D ;
Hertzberg, M ;
Mellman, T ;
Beckham, JC ;
Smith, RD ;
Davison, RM ;
Katz, R ;
Feldman, ME .
PSYCHOLOGICAL MEDICINE, 1997, 27 (01) :153-160